Detalhe da pesquisa
1.
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
J Infect Dis
; 226(1): 119-127, 2022 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34653245
2.
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet Infect Dis
; 23(12): 1360-1369, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517422
3.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Front Immunol
; 13: 852904, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35464450